Методы исследования и составление статей. CONSORT 2010 — объяснение и уточнение: обновленные рекомендации по составлению статьи о рандомизированных клинических исследованиях с параллельными группами. Часть II
Аннотация
В прошлом номере мы опубликовали первую часть CONSORT — Консолидированные (общие) стандарты предоставления результатов о рандомизированных клинических исследованиях (РКИ). Во втором номере журнала мы публикуем вторую, завершающую, часть материалов CONSORT. Данный документ предназначен для более широкого применения, понимания и распространения руководства CONSORT, которое должно помочь в улучшении составления статей рандомизированных исследований. Руководство CONSORT 2010 как разъясняющий и уточняющий документ, а также соответствующий сайт (www.consort-statement. org) должны помочь в улучшении составления статей рандомизированных исследований.
Ключевые слова
Список литературы
1. Tonino PA, De Bruyne B, Pijls NH, Siebert U, Ikeno F, Veer M, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-24.
2. Grant AM, Wileman SM, Ramsay CR, Mowat NA, Krukowski ZH, Heading RC, et al. Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. BMJ 2008;337:a2664.
3. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996e9.
4. Altman DG. Randomisation. BMJ 1991;302:1481-2.
5. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2.
6. May GS, DeMets DL, Friedman LM, Furberg C, Passamani E. The randomized clinical trial: bias in analysis. Circulation 1981;64: 669-73.
7. Altman DG, Cuzick J, Peto J. More on zidovudine in asymptomatic HIV infection. N Engl J Med 1994;330:1758-9.
8. Meinert CL. Beyond CONSORT: need for improved reporting standards for clinical trials. Consolidated Standards of Reporting Trials. JAMA 1998;279:1487-9.
9. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657-62.
10. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
11. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
12. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987;317:426-32.
13. van Loon AJ, Mantingh A, Serlier EK, Kroon G, Mooyaart EL, Huisjes HJ. Randomised controlled trial of magnetic-resonance pelvimetry in breech presentation at term. Lancet 1997;350: 1799-804.
14. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calciumchannel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000;356:366-72.
15. LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133:516-26. [16] Shuster JJ. Median follow-up in clinical trials. J Clin Oncol 1991;9: 191-2.
16. Altman DG, de Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. Br J Cancer 1995;72: 511-8.
17. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298.
18. Diggle L, Deeks J. Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ 2000;321:931-3.
19. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999;353:943-4.
20. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA 2005;294:2203-9. [22] Hughes MD, Pocock SJ. Stopping rules and estimation problems in clinical trials. Stat Med 1988;7:1231-42.
21. Kiri A, Tonascia S, Meinert CL. Treatment effects monitoring committees and early stopping in large clinical trials. Clin Trials 2004;1: 40-7.
22. Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA 2003;289: 2128-31.
23. Altman DG, Dore CJ. Randomisation and baseline comparisons in clinical trials. Lancet 1990;335:149-53.
24. Altman DG, Gore SM, Gardner MJ, Pocock SJ. Statistical guidelines for contributors to medical journals. In: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence: confidence intervals and statistical guidelines. 2nd ed. BMJ Books; 2000. p. 171-90.
25. Lang TA, Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. ACP 1997.
26. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. JAMA 1994;272:125-8.
27. Senn S. Base logic: tests of baseline balance in randomized clinical trials. Clin Res Regulatory Affairs 1995;12:171-82.
28. Altman DG. Comparability of randomised groups. Statistician 1985;34:125-36.
29. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83.
30. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J. Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;132:853-61.
31. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn’s disease. Gastroenterology 2000;119:639-46. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319: 670-4.
32. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319: 670-4.
33. Fields WS, Maslenikov V, Meyer JS, Hass WK, Remington RD, Macdonald M. Joint study of extra-cranial arterial occlusion. V. Progress report of prognosis following surgery or nonsurgical treatment for transient cerebral ischemic attacks and cervical carotid artery lesions. JAMA 1970;211:1993-2003.
34. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB. Analysis of clinical trials by treatment actually received: is it really an option? Stat Med 1991;10:1595-605.
35. Lewis JA, Machin D. Intention to treatdwho should use ITT? Br J Cancer 1993;68:647-50.
36. Lachin JL. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:526.
37. Sheiner LB, Rubin DB. Intention-to-treat analysis and the goals of clinical trials. Clin Pharmacol Ther 1995;57:6-15.
38. Nagelkerke N, Fidler V, Bernsen R, Borgdorff M. Estimating treatment effects in randomized clinical trials in the presence of noncompliance. Stat Med 2000;19:1849-64.
39. Melander H, hlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3.
40. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials 2007;4:350-6.
41. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out? J Fam Pract 2002;51:969-71.
42. Herman A, Botser IB, Tenenbaum S, Chechick A. Intentionto-treat analysis and accounting for missing data in orthopaedic randomized clinical trials. J Bone Joint Surg Am 2009;91:2137-43.
43. Schulz KF, Grimes DA, Altman DG, Hayes RJ. Blinding and exclusions after allocation in randomised controlled trials: survey of published parallel group trials in obstetrics and gynaecology. BMJ 1996;312:742-4.
44. Ruiz-Canela M, Martinez-Gonzalez MA, de Irala-Estevez J. Intention to treat analysis is related to methodological quality. BMJ 2000;320:1007-8.
45. Altman DG. Missing outcomes in randomised trials: addressing the dilemma. Open Med 2009;3:e21-3.
46. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 2004;1: 368-76.
47. Streiner DL. Missing data and the trouble with LOCF. Evid Based Ment Health 2008;11:3-5.
48. Altman DG. Confidence intervals in practice. In: Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with confidence. 2nd ed. BMJ Books; 2000. p. 6-14.
49. Lang TA, Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. ACP 1997.
50. Lang TA, Secic M. How to report statistics in medicine. Annotated guidelines for authors, editors, and reviewers. ACP 1997.
51. Uniform requirements for manuscripts submitted to biomedical journals. International Committee of Medical Journal Editors. Ann Intern Med 1997;126:36-47.
52. Gardner MJ, Altman DG. Confidence intervals rather than P values: estimation rather than hypothesis testing. BMJ 1986;292:746-50.
53. Bailar JC III, Mosteller F. Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. Ann Intern Med 1988;108:266-73.
54. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
55. Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan AW, Cronin E, et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 2008;3:e3081.
56. Bland JM. Quoting intermediate analyses can only mislead. BMJ 1997;314:1907-8.
57. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
58. Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ 1999;319: 1492-5. [61] Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
59. van Linschoten R, van Middelkoop M, Berger MY, Heintjes EM, Verhaar JA, Willemsen SP, et al. Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial. BMJ 2009;339:b4074.
60. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant — the judgment of OSIRIS (open study of infants at high risk of or with respiratory insufficiency — the role of surfactant). Lancet 1992;340:1363-9.
61. Sorensen L, Gyrd-Hansen D, Kristiansen IS, Nexoe J, Nielsen JB. Laypersons’ understanding of relative risk reductions: randomised cross-sectional study. BMC Med Inform Decis Mak 2008;8:31.
62. Bobbio M, Demichelis B, Giustetto G. Completeness of reporting trial results: effect on physicians’ willingness to prescribe. Lancet 1994;343:1209-11.
63. Naylor CD, Chen E, Strauss B. Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness? Ann Intern Med 1992;117:916-21.
64. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47.
65. Tukey JW. Some thoughts on clinical trials, especially problems of multiplicity. Science 1977;198:679-84.
66. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
67. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
68. Oxman AD, Guyatt GH. A consumer’s guide to subgroup analyses. Ann Intern Med 1992;116:78-84. [72] Altman DG. Adjustment for covariate imbalance. In: Armitage P, Colton T, editors. Encyclopedia of biostatistics. John Wiley; 1998. p. 1000-5.
69. Hahn S, Williamson PR, Hutton JL, Garner P, Flynn EV. Assessing the potential for bias in meta-analysis due to selective reporting of subgroup analyses within studies. Stat Med 2000;19:3325-36.
70. Bhandari M, Devereaux PJ, Li P, Mah D, Lim K, Schunemann HJ, et al. Misuse of baseline comparison tests and subgroup analyses in surgical trials. Clin Orthop Relat Res 2006;447:247-51.
71. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:a2299.
72. Ioannidis JP, Evans SJ, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141: 781-8.
73. Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 2000;356:961-7.
74. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43.
75. Gilligan D, Nicolson M, Smith I, Groen H, Dalesio O, Goldstraw P, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007;369:1929-37.
76. Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol 2006;24:3933-8.
77. Pitrou I, Boutron I, Ahmad N, Ravaud P. Reporting of safety results in published reports of randomized controlled trials. Arch Intern Med 2009;169:1756-61.
78. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
79. Horton R. The rhetoric of research. BMJ 1995;310:985-7.
80. Ioannidis JP, Evans SJ, Gotzsche PC, O’Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141: 781-8.
81. Annals of Internal Medicine. Information for authors. Available at www.annals.org (accessed 15 Jan 2008).
82. Docherty M, Smith R. The case for structuring the discussion of scientific papers. BMJ 1999;318:1224-5.
83. Purcell GP, Donovan SL, Davidoff F. Changes to manuscripts during the editorial process: characterizing the evolution of a clinical paper. JAMA 1998;280:227-8.
84. Ioannidis JP. Limitations are not properly acknowledged in the scientific literature. J Clin Epidemiol 2007;60:324-9.
85. Kiviluoto T, Siren J, Luukkonen P, Kivilaakso E. Randomised trial of laparoscopic versus open cholecystectomy for acute and gangrenous cholecystitis. Lancet 1998;351:321-5.
86. Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.
87. Hupperets MD, Verhagen EA, van Mechelen W. Effect of unsupervised home based proprioceptive training on recurrences of ankle sprain: randomised controlled trial. BMJ 2009;339. b2684.
88. Garber J, Clarke GN, Weersing VR, Beardslee WR, Brent DA, Gladstone TR, et al. Prevention of depression in at-risk adolescents: a randomized controlled trial. JAMA 2009;301:2215-24.
89. Campbell D. Factors relevant to the validity of experiments in social settings. Psychol Bull 1957;54:297-312.
90. Rothwell PM. Factors that can affect the external validity of randomised controlled trials. PLoS Clin Trials 2006;1:e9.
91. King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al. Conceptual framework and systematic review of the effects of participants’ and professionals’ preferences in randomised controlled trials. Health Technol Assess 2005;9:1-iv.
92. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8.
93. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
94. Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. BMJ Books; 2001.
95. Dans AL, Dans LF, Guyatt GH, Richardson S. Users’ guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group. JAMA 1998;279:545-9.
96. Smith GD, Egger M. Who benefits from medical interventions? BMJ 1994;308:72-4.
97. McAlister FA. Applying the results of systematic reviews at the bedside. In: Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. BMJ Books; 2001.
98. Bartlett C, Doyal L, Ebrahim S, Davey P, Bachmann M, Egger M, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9:iii-x,1.
99. Bonell C, Oakley A, Hargreaves J, Strange V, Rees R. Assessment of generalisability in trials of health interventions: suggested framework and systematic review. BMJ 2006;333:346-9.
100. Bornhoft G, Maxion-Bergemann S, Wolf U, Kienle GS, Michalsen A, Vollmar HC, et al. Checklist for the qualitative evaluation of clinical studies with particular focus on external validity and model validity. BMC Med Res Methodol 2006;6:56.
101. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:1728-33.
102. Altman DG. Confidence intervals for the number needed to treat. BMJ 1998;317:1309-12.
103. Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1994;330:1107-13.
104. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.
105. Gotzsche PC, Gjorup I, Bonnen H, Brahe NE, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8.
106. Clarke M, Hopewell S, Chalmers I. Reports of clinical trials should begin and end with up-to-date systematic reviews of other relevant evidence: a status report. J R Soc Med 2007;100:187-90.
107. Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999;130:995-1004.
108. Gotzsche PC. Reference bias in reports of drug trials. BMJ 1987;295:654-6.
109. Papp K, Bissonnette R, Rosoph L, Wasel N, Lynde CW, Searles G, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-42.
110. Dickersin K. How important is publication bias? A synthesis of available data. AIDS Educ Prep 1997;9:15-21.
111. Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technol Assess 2000;4:1-115.
112. Williamson PR, Gamble C. Identification and impact of outcome selection bias in meta-analysis. Stat Med 2005;24:1547-61.
113. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Impact of covert duplicate publication on meta-analysis: a case study. BMJ 1997;315:635-40.
114. Times RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
115. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. J R Soc Med 2006;99:337-41.
116. Tonks A. A clinical trials register for Europe. BMJ 2002;325: 1314-5.
117. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003;290: 516-23.
118. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363:1341-5.
119. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
120. Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the Lancet. Lancet 2008;372:201.
121. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Lancet 2005;365:1827-9.
122. Zarin DA, Ide NC, Tse T, Harlan WR, West JC, Lindberg DA. Issues in the registration of clinical trials. JAMA 2007;297:2112-20.
123. Hopewell S, Altman DG, Moher D, Schulz KF. Endorsement of the CONSORT Statement by high impact factor medical journals: a survey of journal editors and journal ‘instructions to authors’. Trials 2008;9:20.
124. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87.
125. Chan AW, Tetzlaff J, Altman D, Gotzsche PC, HrobjartssonA, Krleza-Jeric K, et al. The SPIRIT initiative: defining standard protocol items for randomised trials. Oral presentation at the 16th Cochrane Colloquium: Evidence in the era of globalisation; 2008 Oct 3–7; Freiburg, Germany [abstract]. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2008;102:27.
126. Gregson S, Adamson S, Papaya S, Mundondo J, Nyamukapa CA, Mason PR, et al. Impact and process evaluation of integrated community and clinic-based HIV-1 control: a clusterrandomised trial in eastern Zimbabwe. PLoS Med 2007;4:e102.
127. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 2007;298:1171-9.
128. Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70.
129. Kjaergard LL, Аls-Nielsen B. Association between competing interests and authors’ conclusions: epidemiological study of randomised clinical trials published in the BMJ. BMJ 2002;325:249.
130. Bero L, Oostvogel F, Bacchetti P, Lee K. Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others. PLoS Med 2007;4: e184.
131. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2008;29:109-13.
132. Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA 2003;290:921-8.
133. Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA 2008;299: 1800-12.
134. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62.
135. Campbell MK, Elbourne DR, Altman DG. CONSORT statement: extension to cluster randomised trials. BMJ 2004;328:702-8.
136. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006;295:1152- 60.
137. McAlister FA, Straus SE, Sackett DL, Altman DG. Analysis and reporting of factorial trials: a systematic review. JAMA 2003;289: 2545-53.
138. Senn S. Crossover trials in clinical research. 2nd ed. Wiley; 2002.
139. Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7. iii-173.
140. Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev 2007;. MR000012.
141. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 2001;357:373-80.
142. Schulz KF. Randomised trials, human nature, and reporting guidelines. Lancet 1996;348:596-8.
143. Murray GD. Promoting good research practice. Stat Methods Med Res 2000;9:17-24.
144. Narahari SR, Ryan TJ, Aggithaya MG, Bose KS, Prasanna KS. Evidence-based approaches for the Ayurvedic traditional herbal formulations: toward an Ayurvedic CONSORT model. J Altern Complement Med 2008;14:769-76.
145. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: metaepidemiological study. BMJ 2008;336:601-5.
146. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006;185:263-7.
147. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001;285:1996e9.
148. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;134:657- 62.
149. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-91.
150. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-4.
151. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Ann Intern Med 2003;138:40-4.
152. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147: 573-7.
153. Molnar FJ, Hutton B, Fergusson D. Does analysis using «last observation carried forward» introduce bias in dementia research? CMAJ 2008;179:751-3.
154. Ware JH. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003;348:2136-7.
155. Abraha I, Montedori A, Romagnoli C. Modified intention to treat: frequency, definition and implication for clinical trials [abstract]. Sao Paulo, Brazil: XV Cochrane Colloquium; 2007:86-7.
Рецензия
Для цитирования:
Методы исследования и составление статей. CONSORT 2010 — объяснение и уточнение: обновленные рекомендации по составлению статьи о рандомизированных клинических исследованиях с параллельными группами. Часть II. Проблемы геронауки. 2024;(2):92-111.
For citation:
Research Methods & Reporting. Consort 2010 — Explanation and Elaboration: Updated Guidelines for Reporting Parallel Group Randomised Trials — Part II. Problems of Geroscience. 2024;(2):92-111. (In Russ.)
Просмотров:
262
Послать статью по эл. почте .jpg)
